

COMPANY PROFILE FORM	
Name	BIOMEDCODE HELLAS SA
Short profile	<p>Biomedcode Hellas SA (BioMC) is a spin-off company of Biomedical Sciences Research Center Alexander Fleming. Biomedcode is a contract research organization (CRO) that provides pre clinical drug evaluation models and services in the area of autoimmune and inflammatory diseases. It provides its services to biopharmaceutical companies using unique, humanized, spontaneous, and complex disease animal models. The company's customers include well known global big and small pharmaceutical companies.</p> <p>Full pre-clinical drug evaluation is offered on Biomedcode's transgenic models that develop Rheumatoid Arthritis, Cachexia, Multiple Sclerosis, Inflammatory Bowel Disease and Sepsis. Some of these humanized models include TNFa (TNF alpha), IL-17, IL-33, RANKL, and p55 TNF receptor I (TNFRI). Induced animal models of disease on wild type or transgenic mice are also available, and cover a variety of disease areas (EAE, CIA, etc).</p> <p>In addition, Biomedcode maintains an active R&D program and participates in FP6 (MUGEN network of excellence) and FP7 European projects (MASTERSWITCH, INFLACARE).</p>
Research and Development Activity:	<ol style="list-style-type: none"> 1. Generate and characterize novel humanized transgenic models of disease. 2. Establish and standardize induced models of disease. 3. Establish in vitro assays. 4. Establish pre clinical drug evaluation platform.
Partner search with activity in the following research areas:	<ol style="list-style-type: none"> 1. Autoimmunity 2. Inflammation 3. Cancer

CONTACT	
Name of Contact person:	Lefteris Zacharia
e-mail:	lzacharia@biomedcode.com , praxi@help-forward.gr
Web Site:	www.biomedcode.com

